ScripLess than two months after saying that it would wind down its business of stem cell-based therapies for blood cancers, Vor Bio of the US has bounced back, rebranding as an autoimmune disease company a
ScripIt was Groundhog Day on 2 February. That week, any pharmaceutical groundhogs would have emerged from their burrows, glanced at the shadows of tariffs, a global trade war and weak Chinese demand and sc
ScripAs the business development directors of big pharma companies flock to the annual J.P. Morgan Healthcare conference in San Francisco, important meetings will happen away from the conference ballrooms
ScripPharma Breaks Bread With Trump And RFK Jr But Will They Butt Heads? Donald Trump’s second term as US president does not begin until 20 January but pharma executives spent much of last year wondering w